• Renal Failure and Malignancy, Renal Grand Rounds, Baylor College of Medicine:1996.

 

  • Hyperoxaluria, Renal Grand Rounds, Baylor College of Medicine: 2000.

 

  • Steroid Withdrawal in Kidney Transplantation, Renal Grand Rounds , Baylor College of Medicine: 2001.                                                                            

 

  • A Case of Hypophosphatemia, Renal Grand Rounds, Baylor College of Medicine: 2001.

 

  • Salvage of the failing to mature AVF by endovascular techniques: 2004.

 

  • Renal Ultrasonography: 2005.

 

  • Potential use of Bortezomib in Desensitization Protocol, The kidney Institute: 2009.

 

  • Modern Approach to ESRD, the Desensitization Program. New beginning after organ failure, The Methodist Hospital: 2009.

 

  • Renin-Aldosterone-Angiotensin  System, cardiology staff, Heart Hospital, Doha, Qatar: 2012.

 

  • Introduction to HLA, Part I, Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 08-5-2012.

 

  • Introduction to HLA, part II, Nephrology Section, Hamad Medical Corporation, Doha, Qatar:15-5-2012.

 

  • Evaluation of the humoral arm, part I, Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 29-5-2012.

 

  • Evaluation of the humoral arm, part II, Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 05-06-2012.

 

  • Evaluation of the humoral arm, Part III, Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 19-6-2012.

 

  • The Dysfunctional dialysis access, Nephrology section, Hamad Medical Corporation, Doha, Qatar: 03-7-2012

 

  • HLA Matchmaker, Part I, Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 04-9-2012.

 

  • HLA Matchmaker ,part II, Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 18-9-2012.

 

  • Survival after kidney transplant and evaluation of the potential recipient, Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 02-10-2012.

 

  • The evaluation of the kidney-living donor and risk of donor nephrectomy, Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 09-10-2012.

 

  • The Pathophysiology of Cardiorenal syndrome ,Internal Medicine Department grand round,  Hamad Medical Corporation, Doha, Qatar: 15-10-2012.

 

  • Evaluation of the potential deceased-donor kidney, Part I, Nephrology Section, Hamad Medical Corporation, Doha, Qatar : 06-11-2012.

 

  • Evaluation of the potential deceased-donor kidney, part II, Nephrology Section, Hamad Medical Corporation, Doha, Qatar : 20-11-2012.        

 

  • Pathophysiologic changes associated with brain death and the management of the brain-dead potential donor ,Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 04-12-2012.       

 

  • Introduction to T-cell signaling and novel immunosuppressants, Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 24-2-2013.

 

  • Novel immunosuppressants, part II, Nephrology section, Hamad Medical Corporation, Doha, Qatar: 17-03-2013.       

 

  • Induction Agents in Kidney Transplantation,  Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 31-03-2013.       

 

  • Introduction to bone structure, signaling and novel osteoporosis therapeutics  Part 1,  Nephrology Section, Hamad Medical Corporation, Doha, Qatar : 28-004-2013.

 

  • The Anti-Complement C5-inhibitor-Eculizumab: Indications and clinical usage, Department of Medicine Grand round, Hamad Medical Corporation, Doha, Qatar :09-04-14.

 

  • Cobalamin C deficiency as a cause of aHUS-case presentation, Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 08-6-14.           

 

  • Dysnatremias and uremia: Which dialysis modality and what prescription?  Nephrology Section, Hamad Medical Corporation, Doha, Qatar: 09-11-14.